Menu

PubPeer Wins Appeal on Anonymous Comments

The Michigan Court of Appeals rules that anonymous commenters on the post-publication peer review website are protected under the First Amendment.

Dec 7, 2016
Joshua A. Krisch, Bob Grant

Attorney Bill Burdett (standing), representing “John Doe” in Fazlul Sarkar vs. John Doe, made oral arguments in October 2016 to judges Colleen O’Brien (left) and Elizabeth Gleicher (right) as Alex Abdo (seated), the ACLU lawyer representing PubPeer, looked on.BOB GRANT

The Michigan Court of Appeals issued an opinion in favor of PubPeer today (December 7), ending litigation that pitted the post-publication peer review website against Fazlul Sarkar, a former Wayne State University pathologist who was the subject of research misconduct allegations posted by anonymous commenters on the forum. While the court ruled that Sarkar is still entitled to pursue an independent defamation claim, it affirmed that the online commenters’ identities are protected under the First Amendment.

“This ruling is a critical victory for freedom of speech and scientific inquiry,” Alex Abdo, an attorney with the American Civil Liberties Union (ACLU), which defended PubPeer—as well as anonymous commenters Jane and John Doe—wrote in a statement emailed to The Scientist. “Scientists who anonymously review the work of their peers should not have to fear retribution for exposing the anomalies they find, and the court rightly agreed. Without the breathing space that anonymity provides, free speech and scientific inquiry would suffer.”

The ruling comes on the heels of a December 1 decision by the court to deny the ACLU’s motion to enter into the record the full report from an internal Wayne State University investigation of Sarkar’s work. The Scientist was the first to bring this report to light; the results of the university’s investigation reveal that at least some of the anonymous allegations leveled against Sarkar were likely legitimate. Nicholas Roumel, an attorney at NachtLaw PC representing Sarkar, praised the court’s decision to keep the report from the record. “I’m gratified that the court recognized that this was not a proper action to try to add the investigation report to the appellate record,” he told The Scientist last week.

Update (December 7): “It sucked” that the court did not side with Sarkar, Roumel told The Scientist today, noting that he had not yet had a chance to review the decision in full. Generally speaking, he said, the court’s opinion is “in line with the trend of these cases all over the country.”

“I was hoping we could persuade the court that Michigan should not follow the lead of other courts across the country,” Roumel said. “I guess, if you’re going to lose a case, there’s worse things than losing it to the ACLU, so my hat’s off to them.”

Asked about the next steps for he and Sarkar, Roumel added: “I have no idea what we’ll do next.”

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!